Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. It has anticancer effects by directly targeting tumor metabolism and simultaneously inducing an effective anti-tumor immune response with immunomodulatory and anti-tumor activity.

 

Brand: BCM

 

Solubility: Soluble in DMSO; Soluble in Ethanol. Insoluble in Water.

 

Isomeric SMILES: CC(C)OC(=O)[C@H](CCC(=O)C=[N+]=[N-])NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)C  

 

InChIKey: LQNMCWOJACNQQM-PMACEKPBSA-N  

 

InChI: InChI=1S/C22H27N5O5/c1-13(2)32-22(31)19(9-8-16(29)12-25-23)27-21(30)20(26-14(3)28)10-15-11-24-18-7-5-4-6-17(15)18/h4-7,11-13,19-20,24H,8-10H2,1-3H3,(H,26,28)(H,27,30)/t19-,20-/m0/s1

 

Attribute
[Chem Name]	propan-2-yl (2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-6-diazo-5-oxohexanoate
[Synonym]	Sirpiglenastat; DRP-104
[CAS No.]	2079939-05-0
[Formula]	C22H27N5O5
[Molecular]	441.49
[Form]	Solid Powder
[Storage]	Sealed in dry. Stored at -20°C.

Goods Tag